Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep/visceral RP1 injection in the registrational cohort of anti–PD-1–failed melanoma patients of the IGNYTE trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Gino Kim In, Michael K.K. Wong, Joseph J. Sacco, Eva Muñoz Couselo, Dirk Schadendorf, Georgia Beasley, Jiaxin Niu, Bartosz Chmielowski, Trisha Michel Wise-Draper, Mohammed M. Milhem, Tawnya Lynn Bowles, Katy K. Tsai, Celeste Lebbe, Caroline Gaudy-Marqueste, Adel Samson, Junhong Zhu, Marcus Viana, Jeannie Whit-Shan Hou, Caroline Robert
Institutions: USC Norris Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center, University of Liverpool, Vall d'Hebron Institute of Oncology, Essen University Hospital, Duke University, Duke Cancer Institute, Banner MD Anderson Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Cincinnati, University of Iowa, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, Intermountain Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Centre National de la Recherche Scientifique, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Hôpital de la Timone, University of Leeds, Replimune Group, Inc. (United States), Université Paris-Saclay, Institut Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410816265